tiprankstipranks
Trending News
More News >
Vera Therapeutics (VERA)
NASDAQ:VERA
US Market

Vera Therapeutics (VERA) Stock Forecast & Price Target

Compare
773 Followers
See the Price Targets and Ratings of:

VERA Analyst Ratings

Strong Buy
9Ratings
Strong Buy
9 Buy
0 Hold
0 Sell
Based on 9 analysts giving stock ratings to
Vera
Therapeutics
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

VERA Stock 12 Month Forecast

Average Price Target

$84.13
▲(110.54% Upside)
Based on 9 Wall Street analysts offering 12 month price targets for Vera Therapeutics in the last 3 months. The average price target is $84.13 with a high forecast of $110.00 and a low forecast of $56.00. The average price target represents a 110.54% change from the last price of $39.96.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"19":"$19","42":"$42","65":"$65","88":"$88","111":"$111"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":110,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$110.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":84.13,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$84.13</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":56,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$56.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[19,42,65,88,111],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jun<br/>2025","6":"Sep<br/>2025","9":"Dec<br/>2025","12":"Mar<br/>2026","25":"Mar<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,40.42,45.77230769230769,51.12461538461538,56.47692307692308,61.82923076923077,67.18153846153845,72.53384615384616,77.88615384615385,83.23846153846154,88.59076923076923,93.94307692307692,99.29538461538462,104.64769230769231,{"y":110,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,40.42,43.7823076923077,47.144615384615385,50.50692307692308,53.86923076923077,57.23153846153846,60.59384615384616,63.956153846153846,67.31846153846153,70.68076923076923,74.04307692307692,77.4053846153846,80.7676923076923,{"y":84.13,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,40.42,41.61846153846154,42.816923076923075,44.01538461538462,45.213846153846156,46.41230769230769,47.61076923076923,48.809230769230766,50.00769230769231,51.206153846153846,52.40461538461538,53.60307692307693,54.801538461538456,{"y":56,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":29.93,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":22.02,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":23.75,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":31.74,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 28,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":23,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 28,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":20.95,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":22.61,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":28.79,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":28.46,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":33,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":50.64,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":45.28,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 20, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":40.42,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 24, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$110.00Average Price Target$84.13Lowest Price Target$56.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Wolfe Research Analyst forecast on VERA
Wolfe Research
Wolfe Research
$88
Buy
120.22%
Upside
Upgraded
03/10/26
Analysts Are Bullish on These Healthcare Stocks: Telix Pharmaceuticals (TLPPF), Artiva Biotherapeutics, Inc. (ARTV)
Bank of America Securities Analyst forecast on VERA
Bank of America Securities
Bank of America Securities
$66
Buy
65.17%
Upside
Reiterated
03/09/26
Maintaining the Bull Case on Vera: Atacicept’s Competitive Edge and $2.2B IgAN Peak Sales Upside
H.C. Wainwright Analyst forecast on VERA
H.C. Wainwright
H.C. Wainwright
$90$110
Buy
175.28%
Upside
Reiterated
03/02/26
Vera Therapeutics price target raised to $110 from $90 at H.C. WainwrightVera Therapeutics price target raised to $110 from $90 at H.C. Wainwright
TD Cowen Analyst forecast on VERA
TD Cowen
TD Cowen
$73
Buy
82.68%
Upside
Reiterated
02/27/26
Vera Therapeutics: Strong Atacicept Phase 3 Data and Favorable Regulatory, Commercial Setup Support Buy Rating
LifeSci Capital Analyst forecast on VERA
LifeSci Capital
LifeSci Capital
$90
Buy
125.23%
Upside
Assigned
02/26/26
Vera Therapeutics: Buy Rating Backed by Strong Atacicept Data, Robust Cash Runway, and Large IgAN Market Opportunity
J.P. Morgan Analyst forecast on VERA
J.P. Morgan
J.P. Morgan
Buy
Reiterated
02/26/26
Undervalued IgAN Opportunity: Buy Rating on VERA Driven by Atacicept’s Robust ORIGIN 3 Data and Long-Term Kidney Disease Upside
Guggenheim Analyst forecast on VERA
Unknown Analyst
Guggenheim
Not Ranked
Guggenheim
$56
Buy
40.14%
Upside
Reiterated
02/26/26
Guggenheim Keeps Their Buy Rating on Vera Therapeutics (VERA)
Evercore ISI
$95
Buy
137.74%
Upside
Reiterated
02/17/26
Evercore ISI Sticks to Its Buy Rating for Vera Therapeutics (VERA)
Goldman Sachs Analyst forecast on VERA
Goldman Sachs
Goldman Sachs
$55$95
Buy
137.74%
Upside
Reiterated
12/19/25
Vera Therapeutics (VERA) Receives a Buy from Goldman Sachs
Wedbush Analyst forecast on VERA
Unknown Analyst
Wedbush
Not Ranked
Wedbush
$33
Hold
-17.42%
Downside
Reiterated
12/11/25
Wedbush Keeps Their Hold Rating on Vera Therapeutics (VERA)
Wells Fargo Analyst forecast on VERA
Wells Fargo
Wells Fargo
$70
Buy
75.18%
Upside
Reiterated
11/26/25
Wells Fargo Keeps Their Buy Rating on Vera Therapeutics (VERA)
Jefferies Analyst forecast on VERA
Jefferies
Jefferies
$45
Buy
12.61%
Upside
Reiterated
11/26/25
Vera Therapeutics (VERA) Gets a Buy from Jefferies
Cantor Fitzgerald Analyst forecast on VERA
Cantor Fitzgerald
Cantor Fitzgerald
$100
Buy
150.25%
Upside
Reiterated
11/06/25
Cantor Fitzgerald Reaffirms Their Buy Rating on Vera Therapeutics (VERA)
Raymond James Analyst forecast on VERA
Raymond James
Raymond James
$73
Buy
82.68%
Upside
Reiterated
06/06/25
Vera Therapeutics (VERA) Receives a Buy from Raymond James
Scotiabank Analyst forecast on VERA
Scotiabank
Scotiabank
$55$65
Buy
62.66%
Upside
Reiterated
06/02/25
Vera Therapeutics price target raised to $65 from $55 at ScotiabankVera Therapeutics price target raised to $65 from $55 at Scotiabank
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Wolfe Research Analyst forecast on VERA
Wolfe Research
Wolfe Research
$88
Buy
120.22%
Upside
Upgraded
03/10/26
Analysts Are Bullish on These Healthcare Stocks: Telix Pharmaceuticals (TLPPF), Artiva Biotherapeutics, Inc. (ARTV)
Bank of America Securities Analyst forecast on VERA
Bank of America Securities
Bank of America Securities
$66
Buy
65.17%
Upside
Reiterated
03/09/26
Maintaining the Bull Case on Vera: Atacicept’s Competitive Edge and $2.2B IgAN Peak Sales Upside
H.C. Wainwright Analyst forecast on VERA
H.C. Wainwright
H.C. Wainwright
$90$110
Buy
175.28%
Upside
Reiterated
03/02/26
Vera Therapeutics price target raised to $110 from $90 at H.C. WainwrightVera Therapeutics price target raised to $110 from $90 at H.C. Wainwright
TD Cowen Analyst forecast on VERA
TD Cowen
TD Cowen
$73
Buy
82.68%
Upside
Reiterated
02/27/26
Vera Therapeutics: Strong Atacicept Phase 3 Data and Favorable Regulatory, Commercial Setup Support Buy Rating
LifeSci Capital Analyst forecast on VERA
LifeSci Capital
LifeSci Capital
$90
Buy
125.23%
Upside
Assigned
02/26/26
Vera Therapeutics: Buy Rating Backed by Strong Atacicept Data, Robust Cash Runway, and Large IgAN Market Opportunity
J.P. Morgan Analyst forecast on VERA
J.P. Morgan
J.P. Morgan
Buy
Reiterated
02/26/26
Undervalued IgAN Opportunity: Buy Rating on VERA Driven by Atacicept’s Robust ORIGIN 3 Data and Long-Term Kidney Disease Upside
Guggenheim Analyst forecast on VERA
Unknown Analyst
Guggenheim
Not Ranked
Guggenheim
$56
Buy
40.14%
Upside
Reiterated
02/26/26
Guggenheim Keeps Their Buy Rating on Vera Therapeutics (VERA)
Evercore ISI
$95
Buy
137.74%
Upside
Reiterated
02/17/26
Evercore ISI Sticks to Its Buy Rating for Vera Therapeutics (VERA)
Goldman Sachs Analyst forecast on VERA
Goldman Sachs
Goldman Sachs
$55$95
Buy
137.74%
Upside
Reiterated
12/19/25
Vera Therapeutics (VERA) Receives a Buy from Goldman Sachs
Wedbush Analyst forecast on VERA
Unknown Analyst
Wedbush
Not Ranked
Wedbush
$33
Hold
-17.42%
Downside
Reiterated
12/11/25
Wedbush Keeps Their Hold Rating on Vera Therapeutics (VERA)
Wells Fargo Analyst forecast on VERA
Wells Fargo
Wells Fargo
$70
Buy
75.18%
Upside
Reiterated
11/26/25
Wells Fargo Keeps Their Buy Rating on Vera Therapeutics (VERA)
Jefferies Analyst forecast on VERA
Jefferies
Jefferies
$45
Buy
12.61%
Upside
Reiterated
11/26/25
Vera Therapeutics (VERA) Gets a Buy from Jefferies
Cantor Fitzgerald Analyst forecast on VERA
Cantor Fitzgerald
Cantor Fitzgerald
$100
Buy
150.25%
Upside
Reiterated
11/06/25
Cantor Fitzgerald Reaffirms Their Buy Rating on Vera Therapeutics (VERA)
Raymond James Analyst forecast on VERA
Raymond James
Raymond James
$73
Buy
82.68%
Upside
Reiterated
06/06/25
Vera Therapeutics (VERA) Receives a Buy from Raymond James
Scotiabank Analyst forecast on VERA
Scotiabank
Scotiabank
$55$65
Buy
62.66%
Upside
Reiterated
06/02/25
Vera Therapeutics price target raised to $65 from $55 at ScotiabankVera Therapeutics price target raised to $65 from $55 at Scotiabank
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Vera Therapeutics

3 Months
xxx
Success Rate
10/18 ratings generated profit
56%
Average Return
+18.45%
reiterated a xxx
rating 17 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 55.56% of your transactions generating a profit, with an average return of +18.45% per trade.
1 Year
Rami KatkhudaLifeSci Capital
Success Rate
15/26 ratings generated profit
58%
Average Return
+72.03%
assigned a buy rating 18 days ago
Copying Rami Katkhuda's trades and holding each position for 1 Year would result in 57.69% of your transactions generating a profit, with an average return of +72.03% per trade.
2 Years
xxx
Success Rate
17/23 ratings generated profit
74%
Average Return
+67.66%
reiterated a xxx
rating 18 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 73.91% of your transactions generating a profit, with an average return of +67.66% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

VERA Analyst Recommendation Trends

Rating
Nov 25
Dec 25
Jan 26
Feb 26
Mar 26
Strong Buy
16
21
17
10
7
Buy
3
3
7
7
6
Hold
0
2
8
20
24
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
19
26
32
37
37
In the current month, VERA has received 13 Buy Ratings, 24 Hold Ratings, and 0 Sell Ratings. VERA average Analyst price target in the past 3 months is 84.13.
Each month's total comprises the sum of three months' worth of ratings.

VERA Financial Forecast

VERA Earnings Forecast

Next quarter’s earnings estimate for VERA is -$1.33 with a range of -$1.66 to -$1.16. The previous quarter’s EPS was -$1.39. VERA beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.43% of the time in the same period. In the last calendar year VERA has Performed in-line its overall industry.
Next quarter’s earnings estimate for VERA is -$1.33 with a range of -$1.66 to -$1.16. The previous quarter’s EPS was -$1.39. VERA beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.43% of the time in the same period. In the last calendar year VERA has Performed in-line its overall industry.
No data currently available

VERA Sales Forecast

Next quarter’s sales forecast for VERA is $0.00 with a range of $0.00 to $0.00. The previous quarter’s sales results were $0.00. VERA beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 49.17% of the time in the same period. In the last calendar year VERA has Performed in-line its overall industry.
Next quarter’s sales forecast for VERA is $0.00 with a range of $0.00 to $0.00. The previous quarter’s sales results were $0.00. VERA beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 49.17% of the time in the same period. In the last calendar year VERA has Performed in-line its overall industry.

VERA Stock Forecast FAQ

What is VERA’s average 12-month price target, according to analysts?
Based on analyst ratings, Vera Therapeutics’s 12-month average price target is 84.13.
    What is VERA’s upside potential, based on the analysts’ average price target?
    Vera Therapeutics has 110.54% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is VERA a Buy, Sell or Hold?
          Vera Therapeutics has a consensus rating of Strong Buy which is based on 9 buy ratings, 0 hold ratings and 0 sell ratings.
            What is Vera Therapeutics’s price target?
            The average price target for Vera Therapeutics is 84.13. This is based on 9 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $110.00 ,the lowest forecast is $56.00. The average price target represents 110.54% Increase from the current price of $39.96.
              What do analysts say about Vera Therapeutics?
              Vera Therapeutics’s analyst rating consensus is a Strong Buy. This is based on the ratings of 9 Wall Streets Analysts.
                How can I buy shares of VERA?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.